Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 7/20 | 0.38 |
| ▸ | ATP4B | P51164 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001617 | 0.88 | LTA4H (0.43) | LTA4HKCNH2PPARGPPARA | |
| SCHEMBL2167628 | 0.76 | LTA4H (0.59) | LTA4HKCNH2PPARG | |
| SCHEMBL2169395 | 0.76 | LTA4H (0.61) | LTA4HKCNH2MEN1MAPTKMT2A | |
| SCHEMBL2170516 | 0.75 | LTA4H (0.52) | LTA4HKCNH2MEN1MAPTKMT2A | |
| SCHEMBL2170843 | 0.75 | LTA4H (0.57) | LTA4HKCNH2MEN1MAPTKMT2A | |
| SCHEMBL2169149 | 0.75 | LTA4H (0.61) | LTA4HKCNH2ATP4AATP4B | |
| SCHEMBL2167625 | 0.74 | LTA4H (0.59) | LTA4HKCNH2MEN1MAPTKMT2A | |
| SCHEMBL2168934 | 0.74 | LTA4H (0.59) | LTA4HKCNH2ATP4AATP4B | |
| SCHEMBL2170524 | 0.73 | LTA4H (0.54) | LTA4HKCNH2MEN1MAPTKMT2A | |
| SCHEMBL2170519 | 0.73 | LTA4H (0.56) | LTA4HKCNH2ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KCNH2 2161/4885MEN1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.